Literature DB >> 11458270

Angiogenesis-dependent diseases and angiogenesis therapy.

J Tímár1, B Döme, K Fazekas, A Janovics , S Paku.   

Abstract

The discovery of the molecular mechanisms of physiological vasculogenesis and pathological angiogenesis helped to recognize two classes of diseases: one where the therapeutic angiogenesis can repair the tissue damages (arteriosclerosis, myocardial infarction, limb ischemia) and the other one where inhibition of pathological angiogenesis can cure the disease or delay its progression (retinopathies, benign and malignant angiogenic tumors, progression of malignant tumors). Although there are an exponentially growing number of new synthetic molecules characterized mainly by antiangiogenic properties, the discovery of a large battery of natural pro- and anti-angiogenic factors suggests that this may provide a more physiological approach to treat both class of angiogenesis-dependent diseases in the near future.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11458270     DOI: 10.1007/BF03032573

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  42 in total

Review 1.  The role of alphav integrins during angiogenesis: insights into potential mechanisms of action and clinical development.

Authors:  B P Eliceiri; D A Cheresh
Journal:  J Clin Invest       Date:  1999-05       Impact factor: 14.808

2.  Accutin, a new disintegrin, inhibits angiogenesis in vitro and in vivo by acting as integrin alphavbeta3 antagonist and inducing apoptosis.

Authors:  C H Yeh; H C Peng; T F Huang
Journal:  Blood       Date:  1998-11-01       Impact factor: 22.113

Review 3.  Ocular neovascularization: an epidemiologic review.

Authors:  P Lee; C C Wang; A P Adamis
Journal:  Surv Ophthalmol       Date:  1998 Nov-Dec       Impact factor: 6.048

Review 4.  Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis.

Authors:  D Hanahan; J Folkman
Journal:  Cell       Date:  1996-08-09       Impact factor: 41.582

Review 5.  The clinical manipulation of angiogenesis: pathology, side-effects, surprises, and opportunities with novel human therapies.

Authors:  W D Thompson; W W Li; M Maragoudakis
Journal:  J Pathol       Date:  2000-02       Impact factor: 7.996

6.  Thromboxane A(2) regulation of endothelial cell migration, angiogenesis, and tumor metastasis.

Authors:  D Nie; M Lamberti; A Zacharek; L Li; K Szekeres; K Tang; Y Chen; K V Honn
Journal:  Biochem Biophys Res Commun       Date:  2000-01-07       Impact factor: 3.575

Review 7.  Targeting vascular endothelial growth factor (VEGF) for anti-tumor therapy, by anti-VEGF neutralizing monoclonal antibodies or by VEGF receptor tyrosine-kinase inhibitors.

Authors:  J M Schlaeppi; J M Wood
Journal:  Cancer Metastasis Rev       Date:  1999       Impact factor: 9.264

Review 8.  2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate.

Authors:  V S Pribluda; E R Gubish; T M Lavallee; A Treston; G M Swartz; S J Green
Journal:  Cancer Metastasis Rev       Date:  2000       Impact factor: 9.264

9.  Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression.

Authors:  L Holmgren; M S O'Reilly; J Folkman
Journal:  Nat Med       Date:  1995-02       Impact factor: 53.440

Review 10.  Angiogenesis in cancer, vascular, rheumatoid and other disease.

Authors:  J Folkman
Journal:  Nat Med       Date:  1995-01       Impact factor: 53.440

View more
  24 in total

1.  Acidic and basic fibroblast growth factors involved in cardiac angiogenesis following infarction.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Int J Cardiol       Date:  2010-08-02       Impact factor: 4.164

2.  Embryonic vasculogenesis in nodular melanomas and tumour differentiation.

Authors:  Bhanu Iyengar; Avantika V Singh
Journal:  Pathol Oncol Res       Date:  2011-01-04       Impact factor: 3.201

3.  Vascular endothelial growth factor (VEGF)-A: role on cardiac angiogenesis following myocardial infarction.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Microvasc Res       Date:  2010-04-01       Impact factor: 3.514

Review 4.  Molecular pathology of tumor metastasis III. Target array and combinatorial therapies.

Authors:  József Tímár; Andrea Ladányi; István Peták; András Jeney; László Kopper
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

Review 5.  Incidence and management of ZIv-aflibercept related toxicities in colorectal cancer.

Authors:  Muhammad Wasif Saif; Valerie Relias; Kostas Syrigos; Krishna S Gunturu
Journal:  World J Clin Oncol       Date:  2014-12-10

6.  Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis).

Authors:  Dimitri T Azar
Journal:  Trans Am Ophthalmol Soc       Date:  2006

7.  Angiogenic biomarkers in children with congenital heart disease: possible implications.

Authors:  Nagla T El-Melegy; Nagwa A Mohamed
Journal:  Ital J Pediatr       Date:  2010-04-20       Impact factor: 2.638

8.  Predictive and prognostic value of circulating endothelial cells in non-small cell lung cancer patients treated with standard chemotherapy.

Authors:  Fadi Najjar; Moosheer Alammar; Marroan Bachour; Nissreen Almalla; Moaz Altahan; Ali Alali; Ghassan Al-Massarani
Journal:  J Cancer Res Clin Oncol       Date:  2014-07-19       Impact factor: 4.553

9.  Reactive oxygen species promote angiogenesis in the infarcted rat heart.

Authors:  Wenyuan Zhao; Tieqiang Zhao; Yuanjian Chen; Robert A Ahokas; Yao Sun
Journal:  Int J Exp Pathol       Date:  2009-09-15       Impact factor: 1.925

Review 10.  Matrix metalloproteinase 14 modulates signal transduction and angiogenesis in the cornea.

Authors:  Jin-Hong Chang; Yu-Hui Huang; Christy M Cunningham; Kyu-Yeon Han; Michael Chang; Motoharu Seiki; Zhongjun Zhou; Dimitri T Azar
Journal:  Surv Ophthalmol       Date:  2015-12-02       Impact factor: 6.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.